Penumbra (NYSE:PEN – Get Free Report) is set to issue its quarterly earnings data after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of $0.56 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Penumbra (NYSE:PEN – Get Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.41 earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.01). Penumbra had a return on equity of 7.83% and a net margin of 8.52%. The firm had revenue of $278.70 million during the quarter, compared to analysts’ expectations of $274.94 million. During the same period last year, the company earned $0.23 earnings per share. The business’s revenue for the quarter was up 15.5% compared to the same quarter last year. On average, analysts expect Penumbra to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Penumbra Stock Performance
Penumbra stock opened at $178.43 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.12 and a quick ratio of 3.51. Penumbra has a 1-year low of $170.59 and a 1-year high of $310.51. The firm has a market capitalization of $6.92 billion, a P/E ratio of 75.29, a price-to-earnings-growth ratio of 1.80 and a beta of 0.55. The company’s 50-day moving average is $186.61 and its 200 day moving average is $217.00.
Analyst Ratings Changes
Check Out Our Latest Stock Report on Penumbra
Insider Activity at Penumbra
In related news, CEO Adam Elsesser sold 15,000 shares of Penumbra stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $200.98, for a total transaction of $3,014,700.00. Following the transaction, the chief executive officer now directly owns 942,582 shares of the company’s stock, valued at $189,440,130.36. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Penumbra news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $207.41, for a total value of $124,446.00. Following the completion of the sale, the executive vice president now directly owns 63,488 shares in the company, valued at $13,168,046.08. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $200.98, for a total transaction of $3,014,700.00. Following the completion of the sale, the chief executive officer now owns 942,582 shares of the company’s stock, valued at $189,440,130.36. The disclosure for this sale can be found here. Insiders have sold a total of 31,970 shares of company stock valued at $6,428,404 over the last ninety days. 5.00% of the stock is owned by company insiders.
Penumbra Company Profile
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Featured Articles
- Five stocks we like better than Penumbra
- Why Are These Companies Considered Blue Chips?
- Is Crypto Cool Again? What Stocks You Should Be Watching
- 3 Warren Buffett Stocks to Buy Now
- Why Call Options Volume for These 2 Stocks Spiked Together
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.